Company Overview and News
Midstream posted another strong week overall, and MLPs led the way again, up 3.5% for a second straight week. The midstream rally couldn't be stopped by another 13 basis points added to the U.S. 10-year interest rate. The rally even withstood a Tweet from President Trump about how oil prices are too high. As good as the overall week turned out, the rally was confined to just 2 days, with negative returns in the other 3, just like last week.
LONDON, UK / ACCESSWIRE / February 05, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Oil & Gas – Midstream industry: Inter Pipeline, AltaGas, Keyera, and Gibson Energy. Access our complimentary up-to-the-minute research reports by becoming an online member now:
LONDON, UK / ACCESSWIRE / January 05, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Oil & Gas – Midstream industry: Inter Pipeline, AltaGas, Keyera, and Gibson Energy. Access our complimentary up-to-the-minute research reports by becoming an online member now:
MLP optimism continues to build, as MLPs shrugged off higher interest rates that hurt other yield-oriented securities to gain another 0.5% this week. MLPs are now up more than 8% off the late November bottom. Outside of the changes to the tax backdrop, not much else changed this week. There was some volatility early in the week, with MLPs threatening two straight 1% decline days before a late rally Wednesday and follow-through the rest of the week helped MLPs recover.
Investment Thesis: We are not fans of companies which bite off more than they can chew, but this project really is a game-changer, and Inter Pipeline (OTCPK:IPPLF) has our support.
CALGARY, Alberta (Reuters) - Calgary-based Inter Pipeline Ltd (IPL.TO) said on Monday it will build a C$3.5 billion ($2.7 billion) petrochemical plant in central Alberta, taking advantage of the provincial government’s subsidies for such facilities.
LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Oil & Gas – Midstream industry: Inter Pipeline, AltaGas, Keyera, and Gibson Energy. Access our complimentary up-to-the-minute research reports by becoming an online member now:
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET